» Articles » PMID: 19363028

Antibiotic Resistance in Mycobacterium Tuberculosis: Peroxidase Intermediate Bypass Causes Poor Isoniazid Activation by the S315G Mutant of M. Tuberculosis Catalase-peroxidase (KatG)

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2009 Apr 14
PMID 19363028
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

KatG (catalase-peroxidase) in Mycobacterium tuberculosis is responsible for activation of isoniazid (INH), a pro-drug used to treat tuberculosis infections. Resistance to INH is a global health problem most often associated with mutations in the katG gene. The origin of INH resistance caused by the KatG[S315G] mutant enzyme is examined here. Overexpressed KatG[S315G] was characterized by optical, EPR, and resonance Raman spectroscopy and by studies of the INH activation mechanism in vitro. Catalase activity and peroxidase activity with artificial substrates were moderately reduced (50 and 35%, respectively), whereas the rates of formation of oxyferryl heme:porphyrin pi-cation radical and the decay of heme intermediates were approximately 2-fold faster in KatG[S315G] compared with WT enzyme. The INH binding affinity for the resting enzyme was unchanged, whereas INH activation, measured by the rate of formation of an acyl-nicotinamide adenine dinucleotide adduct considered to be a bactericidal molecule, was reduced by 30% compared with WT KatG. INH resistance is suggested to arise from a redirection of catalytic intermediates into nonproductive reactions that interfere with oxidation of INH. In the resting mutant enzyme, a rapid evolution of 5-c heme to 6-c species occurred in contrast with the behavior of WT KatG and KatG[S315T] and consistent with greater flexibility at the heme edge in the absence of the hydroxyl of residue 315. Insights into the effects of mutations at residue 315 on enzyme structure, peroxidation kinetics, and specific interactions with INH are presented.

Citing Articles

Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in ?.

Abbadi B, Rodrigues-Junior V, da Silva Dadda A, Pissinate K, Villela A, Campos M Front Microbiol. 2018; 9:880.

PMID: 29765372 PMC: 5938375. DOI: 10.3389/fmicb.2018.00880.


Modeling the structural origins of drug resistance to isoniazid via key mutations in Mycobacterium tuberculosis catalase-peroxidase, KatG.

Marney M, Metzger R, Hecht D, Valafar F Tuberculosis (Edinb). 2018; 108:155-162.

PMID: 29523317 PMC: 7330162. DOI: 10.1016/j.tube.2017.11.007.


Mutual synergy between catalase and peroxidase activities of the bifunctional enzyme KatG is facilitated by electron hole-hopping within the enzyme.

Njuma O, Davis I, Ndontsa E, Krewall J, Liu A, Goodwin D J Biol Chem. 2017; 292(45):18408-18421.

PMID: 28972181 PMC: 5682954. DOI: 10.1074/jbc.M117.791202.


Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: insights from molecular dynamics simulations.

Pimentel A, Scodro R, Caleffi-Ferracioli K, Dias Siqueira V, Zanetti Campanerut-Sa P, Lopes L J Mol Model. 2017; 23(4):121.

PMID: 28303436 DOI: 10.1007/s00894-017-3290-3.


Isoniazid and thioacetazone may exhibit antitubercular activity by binding directly with the active site of mycolic acid cyclopropane synthase: Hypothesis based on computational analysis.

Banerjee D, Bhattacharyya R Bioinformation. 2012; 8(16):787-9.

PMID: 23055630 PMC: 3449388. DOI: 10.6026/97320630008787.


References
1.
Gegia M, Mdivani N, Mendes R, Li H, Akhalaia M, Han J . Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations. Antimicrob Agents Chemother. 2007; 52(2):725-9. PMC: 2224719. DOI: 10.1128/AAC.01124-07. View

2.
Morlock G, Metchock B, Sikes D, Crawford J, Cooksey R . ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003; 47(12):3799-805. PMC: 296216. DOI: 10.1128/AAC.47.12.3799-3805.2003. View

3.
Sepkowitz K . Tuberculosis control in the 21st century. Emerg Infect Dis. 2001; 7(2):259-62. PMC: 2631725. DOI: 10.3201/eid0702.010222. View

4.
Engleder M, Regelsberger G, Jakopitsch C, Furtmuller P, Ruker F, Peschek G . Nucleotide sequence analysis, overexpression in Escherichia coli and kinetic characterization of Anacystis nidulans catalase-peroxidase. Biochimie. 2000; 82(3):211-9. DOI: 10.1016/s0300-9084(00)00204-2. View

5.
Ranguelova K, Girotto S, Gerfen G, Yu S, Suarez J, Metlitsky L . Radical sites in Mycobacterium tuberculosis KatG identified using electron paramagnetic resonance spectroscopy, the three-dimensional crystal structure, and electron transfer couplings. J Biol Chem. 2007; 282(9):6255-64. PMC: 1885898. DOI: 10.1074/jbc.M607309200. View